| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Division of Gastroenterology and Department of Research, University Hospital, CH-4031 Basel, Switzerland
 |
ABSTRACT |
|---|
 TOP
 ABSTRACT
 INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
Cholecystokinin (CCK) interacts with neural signals to induce satiety in several species, but the mechanisms are unclear. We therefore tested the hypothesis that alimentary CCK (CCK-A) receptors mediate the interaction of CCK with an appetizer on food intake in humans. CCK octapeptide (CCK-8, 0.75 µg infused over 10 min) or saline (placebo) with concomitant infusions of saline (placebo) or loxiglumide, a specific CCK-A antagonist, was infused into 16 healthy men with use of a double-blind, four-period design. All subjects received a standard 400-ml appetizer (amounting to 154 kcal) but were free to eat and drink thereafter as much as they wished. The effect of these infusions on feelings of hunger and satiety and on food intake was quantified. CCK-8 induced a reduction in calorie intake (P < 0.05) compared with saline. Furthermore, a decrease in hunger feelings (P < 0.05, saline-CCK-8 vs. all other treatments) and an increase in fullness were observed. These effects were antagonized for hunger and fullness by loxiglumide. We conclude that CCK-8 interacts with an appetizer to modulate satiety in humans. These effects are mediated by CCK-A receptors.
appetite; alimentary cholecystokinin receptors; loxiglumide
| |
INTRODUCTION |
|---|
|
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
THE EFFECT ON FOOD INTAKE resulting from the interaction between a cholecystokinin (CCK) infusion and gastric distension has previously been explored in humans (26). Different levels of gastric distension were induced by giving variable amounts of a liquid preload to healthy volunteers together with a short-term infusion of intravenous CCK octapeptide (CCK-8) before a regular meal was presented. The results suggested that gastric distension interacts with CCK-8 to reduce food intake in humans. This interaction was first reported in rats (1): a greater reduction in food intake was observed when CCK-8 was injected after the animals had already eaten some food than when CCK-8 was given without a preload of food. However, the rat study used a sham-feeding preparation, which may have obscured the contribution of the gastric phase to the regulation of food intake. A clear role for gastric distension has therefore not been established, and it is possible that an interaction of gastric distension with oral and intestinal stimuli is responsible for the reported effects. However, several additional lines of evidence support the hypothesis that CCK can suppress food intake in a variety of animals and also in humans (2, 6-8, 14, 16, 18, 23, 35, 39).
Further exploration of the interaction between CCK and the stomach thus appeared to be a fruitful line of investigation to better understand the regulation of food intake in humans. The availability of potent and selective alimentary CCK (CCK-A) receptor antagonists has made it possible to continue these investigations. Loxiglumide (Lox) is one of these specific CCK-A receptor antagonists available for human use (11, 12, 32, 33). Lox is therefore a useful tool to test the hypothesis that peripheral CCK-A receptor types are responsible for mediating the interactions of CCK with a preload on food intake in humans.
| |
METHODS |
|---|
|
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
Subjects. Thirty-two men, aged 21-33 (mean 24) yr, participated in the study. The weight of all subjects was within a normal range for their age, gender, and height. Each subject gave written informed consent for the study. The protocol was approved by the Human Ethics Committee of the University Hospital in Basel. Before acceptance, each participant was required to complete a medical interview, received a full physical examination, and participated in an initial laboratory screening. No subject was taking any medication or had a history of food allergies or dietary restrictions.
Experimental procedure.
A randomized, double-blind crossover design was used for four
treatments, separated by 
7 days, in each subject. On the day of the
experiment, each subject ate breakfast if this was his normal custom,
but no snacks were allowed after 8 AM. At noon, the experiment started
with the first continuous infusion. The treatments were identical in
design, except for the intravenous infusions (Fig.
1). Sixteen subjects participated in the
study.
|
1 · h1) throughout
the entire experiment instead of saline, combined with either saline or
CCK-8, in the dose mentioned above, as short infusions. The dose of Lox
was chosen from previous experiments (11, 12,
32, 33). This dose of Lox is able to abolish meal-stimulated gallbladder contraction.
After having started the infusion, the subjects scored their subjective
feelings for hunger and fullness at 15-min intervals throughout each
treatment by use of a visual analog scale from 1 through 10 and
indicated their scores on a questionnaire. The scale and scores were
designed and described in detail previously (4,
37, 38). Briefly, a score of 0 for hunger
indicated that the subject was not hungry at all, 2 indicated
"slightly hungry," 5 indicated "moderately hungry," 8 indicated
"very hungry," and 10 indicated "absolutely ravenous." The
score for fullness was similar.
At 45 min after the start of the infusion of Lox or saline, a preload
of 400 ml of banana shake was served to the subjects. The preload used
in this study is based on experiments performed by Muurahainen et al.
(26). The shake was made of 100 g of whey, 16 g
of sugar, and 100 g of blenderized banana and mixed with water to
a total amount of 400 ml. The composition of the preload was 35.8 g of carbohydrates, 0.4 g of fat, and 1.7 g of protein amounting to 154 kcal. At 15 min after ingestion of the preload, the
second infusion of CCK-8 or saline was started and administered for 10 min.
At 5 min after the start of this second infusion, a standard meal was
presented to the subjects, and they were invited to eat and drink as
much as they wished for 60 min. The meal consisted of 1)
orange juice, 2) ham sandwiches (wheat bread, butter, and ham), 3) chocolate pudding, and 4) coffee. Coffee
could be sweetened with sugar if desired, and cream could be added (5 g
sugar = 20 kcal, 12 g cream = 20 kcal). The order of
food intake had to follow the above schedule. The nutritive values of
the test meals are given in Table 1. The
energy conversion relied on manufacturer's specifications and was not
controlled by calorimetry. To reduce the participant's awareness of
the amount of food eaten, food was presented in small samples and in
excess.
|
Plasma hormone determinations. Plasma immunoreactive CCK concentrations were measured by a sensitive RIA based on the antiserum OAL-656, which recognizes the sulfated tyrosine residue of CCK-8 but has no relevant cross-reactivity with sulfated gastrin (<1%) and does not cross-react with unrelated gastrointestinal peptides (10). Plasma samples were extracted with ethanol. The detection limit of the assay was 5 pg/ml plasma with CCK-33 as a standard. Details of the assay have previously been described (12, 20, 21).
Statistical analysis. The amount eaten and drunk and the corresponding calorie intake were analyzed with repeated-measures ANOVA on treatments with use of the GLM procedure in the SAS software package (30). In the event of significant differences, ANOVA was followed by Scheffé's multicomparison test for pairwise comparisons (29). The scores for hunger and fullness were compared at the different time points before and after meals, with GLM repeated-measures ANOVA accounting for treatment effects as well as between-subject factor. Scheffé's test was used as a post hoc multicomparison test for treatment effects (29, 30).
| |
RESULTS |
|---|
|
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
Food intake.
The results on the different food variables are given in Table
2. They can be summarized as follows.
1) The amount of food consumed was significantly less after
saline-CCK-8 (P < 0.001) than after all other
conditions, which were not different from each other. 2)
Fluid consumption was significantly (P < 0.02) reduced
after saline-CCK-8 compared with the control treatment (saline-saline),
and this reduction was prevented by Lox. 3) As a result,
total energy intake was decreased after saline-CCK-8 compared with
saline-saline, but the difference did not reach statistical
significance (P = 0.054). However, when the two CCK treatments were averaged across the two levels of Lox (i.e.,
CCK-Lox + CCK-saline), the difference from the saline levels
(saline-Lox and saline-saline) was significant, and CCK reduced energy
intake by 184 ± 48 kcal (t = 3.83, P = 0.04, 45 degrees of freedom). In fact, the only
significant differences for total energy intake were between
saline-CCK-8 and Lox-CCK-8 and between saline-CCK-8 and Lox-saline
(Table 2). Thus CCK-8 alone did not significantly reduce calorie
intake, but Lox-saline significantly raised calorie intake compared
with saline-saline. Therefore, in the present study, CCK-8
significantly decreased energy intake only when Lox was given. Lox, on
the other hand, increased calorie consumption regardless of whether
CCK-8 or saline was infused.
|
CCK-8-saline (saline-Lox CCK-8-Lox). These data are given in Table
3. The calculations provide support for
the statements that CCK-8 indeed reduced the amount of food eaten and
the amount of fluid consumed and that these effects were reversed by
Lox. No significant effect was seen for calorie intake, however.
|
Eating ratings.
As expected, hunger ratings fell and fullness ratings rose after the
subjects had drunk the preload. The effect on the visual analog
scale was most pronounced with saline-CCK-8 and was
statistically significant (P < 0.05) during the CCK-8
infusion compared with all other treatments (Fig.
2). In fact, CCK-8 did significantly reduce hunger and increased fullness in the premeal period, and these
effects were reversed by Lox. Lox alone, on the other hand, did not
significantly affect hunger or fullness feelings. These data indicate
that CCK-8 interacts with a preload to induce early satiety, an effect
that is mediated by CCK-A receptors. No statistical differences in
hunger or fullness ratings were observed during meal intake for
fullness or hunger scores between any treatment.
|
Plasma CCK.
During the control treatment (saline-saline), plasma CCK remained
stable in the premeal period. Banana shake (400 ml) did not stimulate
plasma CCK concentrations (Fig. 3).
During CCK-8 infusion, a significant increase (P < 0.01) in plasma CCK levels was obtained. Interestingly, in the
treatment with intravenous Lox administration, the preload of banana
shake induced a significant increase in plasma CCK (P < 0.05). The highest increase in plasma CCK was seen with CCK-8-Lox
(Fig. 3).
|
| |
DISCUSSION |
|---|
|
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
The role of the preabsorptive release of CCK in the production of meal-ending satiety has been extensively studied in animals (5, 9, 24, 27, 35).
The evidence in humans for CCK as a peripheral satiety signal is less clear. In 1981, Kissileff et al. (14) reported that infusion of exogenous CCK-8 decreased liquid meal intake in human volunteers. Recently, Lieverse and co-workers (18) extended these observations by showing that CCK infusions leading to physiological plasma CCK levels significantly increased satiety in humans. However, not all studies found consistent effects of CCK on satiety in humans. Infusion of exogenous CCK at plasma levels termed physiological (because they induced postprandial gallbladder contraction or pancreatic enzyme secretion) failed to affect food intake and satiety effects in healthy human subjects in at least two studies (19, 31). Different results have also been obtained with different specific CCK-A receptor antagonists in healthy volunteers: oral administration of MK-329, also known as devazepide, induced a significant increase in hunger feelings, suggesting that endogenous CCK is indeed involved in the physiological control of food intake (40). Our previous results with Lox are in contrast with the findings obtained with MK-329: intravenous infusion of the CCK-A receptor antagonist Lox failed to reverse fat- or phenylalanine-induced inhibition of food intake and satiety, suggesting that CCK is not important under these circumstances (4, 28). It is, however, doubtful that these last experiments used the optimal conditions for demonstrating CCK's effectiveness. The compounds (fat and phenylalanine) were perfused to the duodenum, thereby bypassing the stomach, whereas a large gastric distension accompanied by CCK release seems to be important for CCK to have an effect (4, 25, 26, 28). Also, rather large loads of fat and phenylalanine were used in these last experiments, and this may have affected the results by possibly disturbing gastrointestinal motility and thus overruling the satiety effects of CCK. In support of the role of CCK are additional recent observations of Lieverse and co-workers (17), who demonstrated that a small load of intraduodenal fat increased satiety mainly through the effects of CCK.
With this background in mind, we extended the hypothesis of Muurahainen et al. (26), which suggested that a preload of a liquid meal with a concomitant infusion of CCK-8 can reduce food intake in humans. As another extension to the previous work, the CCK-A receptor antagonist Lox was used as a tool in the present experiments. The results show that a preload of banana shake together with CCK-8 infusion induces a significant reduction in food intake compared with the control experiment (saline-saline infusion). The effects of CCK-8 seemed to be specific, inasmuch as the CCK-A receptor antagonist Lox was able to antagonize the effects of CCK-8. The average calorie intake was even increased by ~10% in the experiments with Lox-saline administration, suggesting indeed that CCK-8 through its A receptor modulates food intake in humans. We interpret the results with Lox as compelling evidence that endogenous CCK released by food ingestion curtails hunger feelings and induces early satiety in humans, implying that CCK is indeed one of several physiological satiety signals in humans.
This study differs from various other human studies in several respects. In previous studies (14, 25, 36) in which CCK-8 induced satiety, CCK plasma levels were not measured, and it is very possible that unphysiological plasma CCK levels were obtained. Here, we used two different approaches: 1) we infused CCK-8 at a low concentration, and 2) we used a specific CCK-A receptor antagonist as a specific tool.
Along these lines, we have shown that CCK indeed can modulate satiety in humans and that these effects are probably mediated by CCK-A receptors. Which mechanism is responsible for the satiety effect of CCK? Observations based mainly on animal work suggest that the inhibitory effects of CCK on gastric emptying rates may contribute to its satiety-producing properties (3). These findings could explain the negative results obtained in the study with Lox and intraduodenal nutrients where the stomach was bypassed (4, 28). However, even though intravenous CCK has been shown to slow gastric emptying of liquid meals in humans (6, 16, 23), it has to be kept in mind that inhibition of gastric emptying and inhibition of food intake can be independent actions. The possibility even exists that CCK primarily acts on satiety through signals that act exclusively on abdominal vagal afferent fibers but are unrelated to gastric distension or gastric emptying rates. Along this line of argumentation, Joyner and co-workers (13) observed in rats that the satiety potency of CCK-8 was equivalent in sham- and real-feeding experiments, thus implying that under certain conditions the satiating effect is independent of gastric distension, because gastric distension does not occur during sham feeding (13). In contrast to this rat study, Melton and co-workers (22) noted in women that ratings of hunger were higher with CCK-8 than with saline administration when a gastric balloon was inflated to the same gastric pressure. In addition, fullness ratings rose and hunger feelings declined more steeply in relation to gastric pressure when CCK-8 was infused. These data indicate that the stomach is important in amplifying signals that regulate hunger and satiety independently of other aspects such as food composition.
When the plasma CCK concentrations are compared with digestive processes such as postprandial gallbladder contraction, they can be termed physiological. However, it is not known what level of CCK is necessary to achieve concentrations at the receptor that are able to reduce food intake. The banana shake itself did not release any CCK. Therefore, it is unlikely that circulating levels of CCK mediated these effects. The lack of increase in CCK is not surprising, because we chose a preload composed mainly of carbohydrates, which are poor CCK secretagogues (15). In agreement with previous observations, we noticed that Lox did not influence basal plasma CCK concentrations (11, 23, 34), but it did induce a considerable increase in plasma CCK after the preload was given. This finding is interesting, inasmuch as it suggests that gastric distension participates in the control of CCK release, but these observations require further confirmation. An augmented CCK release during Lox administration has previously been documented and related to a diminished bile acid and/or enzyme concentration in the lumen of the proximal small intestine because of diminished gallbladder emptying or inhibition of exocrine pancreatic secretion (11, 23, 34). This increase in plasma CCK has been explained by a feedback control of intraluminal bile and/or enzyme concentration, which, in turn, regulates CCK release (11, 23, 34).
The results of the visual analog scales are instructive. The fullness score was significantly higher only during CCK-8 infusions. In parallel, the hunger ratings were lower with saline-CCK-8. Lox completely blocked this effect, demonstrating that it is mediated by peripheral CCK-A receptors. Lox alone even induced a tendency for greater hunger feelings and lower fullness signals, implying that these effects were truly mediated by CCK-A receptors.
In conclusion, the results in our study lend support to the hypothesis that CCK-like peptides are endogenous signals involved in the control of food intake in humans; these signals are mediated by CCK-A receptors. Further investigations are needed to define the adequate stimuli for CCK and its role in the control of human food intake. Given the importance of reducing fat and calorie intake for public health to understand and prevent obesity, further efforts to comprehend these basic mechanisms are likely to yield important fundamental and therapeutic information.
Perspectives
The investigation of human eating behavior, especially the regulation of appetite and satiety, has become a very active field of research with the potential for the development of a specific therapy for obesity. Little is known about the biochemical processes that control hunger and satiety. However, there is evidence that preabsorptive factors are important cofactors in this regulation. Fat ingestion stimulates the secretion of a number of gastrointestinal hormones, including CCK. CCK has been shown to affect the short-term control of food intake in animals and humans during a test meal. Therefore, CCK has been proposed to act as a hormonal satiety signal.A series of recent studies in humans has shown that peripherally induced CCK can reduce energy intake and modulate subjective appetite sensations. Along this line, the present study illustrates that CCK-8 modulates food intake when given with a preload, supporting a physiological role for the peptide in regulating appetite. However, many questions remain unanswered. Does CCK interact with other gastrointestinal hormones released in response to intraduodenal fat that have been proposed to regulate food intake (glucagon-like peptide-1 and peptide YY)? What is the mechanism of action? Are the effects of CCK mediated by abdominal nerves? CCK dose dependently inhibits gastric emptying; does inhibition of gastric emptying itself reduce food intake, perhaps in association with distension plus oral and intestinal factors? The regulation of food intake is a complex system; much more information is necessary to understand the basic physiological mechanisms that control food intake and satiety. Elucidation of these mechanisms will increase the understanding of the role of dietary nutrients in the regulation of appetite and body weight and the development of overweight and obesity.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Carita Frei for excellent editorial assistance.
| |
FOOTNOTES |
|---|
This work was supported in part by Swiss National Science Foundation Grant 3200-40604-91.
Some data from this study were presented at the Annual Meeting of the American Gastroenterological Association (New Orleans, LA, May 1994) and published in abstract form.
Address for reprint requests and other correspondence: C. Beglinger, Div. of Gastroenterology, University Hospital, CH-4031 Basel, Switzerland (E-mail: beglinger{at}tmr.ch).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
Received 19 November 1997; accepted in final form 4 February 2000.
| |
REFERENCES |
|---|
|
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
1.
Antin, J,
Gibbs J,
and
Smith GP.
Cholecystokinin interacts with pregastric food stimulation to elicit satiety in the rat.
Physiol Behav
20:
67-70,
1978[Medline].
2.
Bado, A,
Rodriguez M,
Lewin MJ,
Martinez J,
and
Dubrasquet M.
Cholecystokinin suppresses food intake in cats: structure-activity characterization.
Pharmacol Biochem Behav
31:
297-303,
1988[ISI][Medline].
3.
Dockray, GJ.
Vagally mediated actions of CCK.
In: CCK Antagonists in Gastroenterolgy, edited by Adler G,
and Beglinger C.. Berlin: Springer, 1991, p. 56-62.
4.
Drewe, J,
Gadient A,
Rovati LC,
and
Beglinger C.
Role of circulating cholecystokinin in control of fat-induced inhibition of food intake in humans.
Gastroenterology
102:
1654-1659,
1992[ISI][Medline].
5.
Ebenezer, IS,
de la Riva C,
and
Baldwin BA.
Effects of the CCK receptor antagonist MK-329 on food intake in pigs.
Physiol Behav
47:
145-148,
1990[Medline].
6.
Fried, M,
Erlacher U,
Schwizer W,
Lochner C,
Koerfer J,
Beglinger C,
Jansen JB,
Lamers CB,
Harder F,
Bischof-Delaloye A,
Role of cholecystokinin in the regulation of gastric emptying and pancreatic enzyme secretion in humans. Studies with the cholecystokinin-receptor antagonist loxiglumide.
Gastroenterology
101:
503-511,
1991[ISI][Medline].
7.
Gibbs, J,
Young RC,
and
Smith GP.
Cholecystokinin decreases food intake in rats.
J Comp Physiol Psychol
84:
488-495,
1973[ISI][Medline].
8.
Gibbs, J,
Young RC,
and
Smith GP.
Cholecystokinin elicits satiety in rats with open gastric fistulas.
Nature
245:
323-325,
1973[Medline].
9.
Gregory, PC,
McFadyen M,
and
Rayner DV.
Duodenal infusion of fat, cholecystokinin secretion and satiety in the pig.
Physiol Behav
45:
1021-1024,
1989[Medline].
10.
Hashimura, E,
Shimizu F,
Nishino T,
Imagawa K,
Tateishi K,
and
Hamaoka T.
Production of rabbit antibody specific for amino-terminal residues of cholecystokinin octapeptide (CCK-8) by selective suppression of cross-reactive antibody response.
J Immunol Methods
55:
375-387,
1982[ISI][Medline].
11.
Hildebrand, P,
Beglinger C,
Gyr K,
Jansen JB,
Rovati LC,
Zuercher M,
Lamers CB,
Setnikar I,
and
Stalder GA.
Effects of a cholecystokinin receptor antagonist on intestinal phase of pancreatic and biliary responses in man.
J Clin Invest
85:
640-646,
1990.
12.
Hildebrand, P,
Ensinck JW,
Ketterer S,
Delco F,
Mossi S,
Bangerter U,
and
Beglinger C.
Effect of a cholecystokinin antagonist on meal-stimulated insulin and pancreatic polypeptide release in humans.
J Clin Endocrinol Metab
72:
1123-1129,
1991[Abstract].
13.
Joyner, K,
Smith GP,
and
Gibbs J.
Abdominal vagotomy decreases the satiating potency of CCK-8 in sham and real feeding.
Am J Physiol Regulatory Integrative Comp Physiol
264:
R912-R916,
1993
14.
Kissileff, HR,
Pi-Sunyer FX,
Thornton J,
and
Smith GP.
C-terminal octapeptide of cholecystokinin decreases food intake in man.
Am J Clin Nutr
34:
154-160,
1981
15.
Liddle, RA,
Goldfine ID,
Rosen MS,
Taplitz RA,
and
Williams JA.
Cholecystokinin bioactivity in human plasma. Molecular forms, responses to feeding, and relationship to gallbladder contraction.
J Clin Invest
75:
1144-1152,
1985.
16.
Liddle, RA,
Morita ET,
Conrad CK,
and
Williams JA.
Regulation of gastric emptying in humans by cholecystokinin.
J Clin Invest
77:
992-996,
1986.
17.
Lieverse, RJ,
Jansen JB,
Masclee AA,
Rovati LC,
and
Lamers CB.
Effect of a low dose of intraduodenal fat on satiety in humans: studies using the type A cholecystokinin receptor antagonist loxiglumide.
Gut
35:
501-505,
1994
18.
Lieverse, RJ,
Jansen JB,
Masclee AM,
and
Lamers CB.
Satiety effects of cholecystokinin in humans.
Gastroenterology
106:
1451-1454,
1994[ISI][Medline].
19.
Lieverse, RJ,
Jansen JB,
van de Zwan A,
Samson L,
Masclee AA,
and
Lamers CB.
Effects of a physiological dose of cholecystokinin on food intake and postprandial satiation in man.
Regul Pept
43:
83-89,
1993[ISI][Medline].
20.
Matzinger, D,
Gutzwiller JP,
Drewe J,
Orban A,
Engel R,
D'Amato M,
Rovati L,
and
Beglinger C.
Inhibition of food intake in response to intestinal lipid is mediated by cholecystokinin in humans.
Am J Physiol Regulatory Integrative Comp Physiol
277:
R1718-R1724,
1999
21.
Meier, R,
Hildebrand P,
Thumshirn M,
Albrecht C,
Studer B,
Gyr K,
and
Beglinger C.
Effect of loxiglumide, a cholecystokinin antagonist, on pancreatic polypeptide release in humans.
Gastroenterology
99:
1757-1762,
1990[ISI][Medline].
22.
Melton, PM,
Kissileff HR,
and
Pi-Sunyer FX.
Cholecystokinin (CCK-8) affects gastric pressure and ratings of hunger and fullness in women.
Am J Physiol Regulatory Integrative Comp Physiol
263:
R452-R466,
1992
23.
Meyer, BM,
Werth BA,
Beglinger C,
Hildebrand P,
Jansen JB,
Zach D,
Rovati LC,
and
Stalder GA.
Role of cholecystokinin in regulation of gastrointestinal motor functions.
Lancet
2:
12-15,
1989[ISI][Medline].
24.
Moran, TH,
and
McHugh PR.
Gastric and nongastric mechanisms for satiety action of cholecystokinin.
Am J Physiol Regulatory Integrative Comp Physiol
254:
R628-R632,
1988
25.
Muurahainen, N,
Kissileff HR,
Derogatis AJ,
and
Pi-Sunyer FX.
Effects of cholecystokinin-octapeptide (CCK-8) on food intake and gastric emptying in man.
Physiol Behav
44:
645-649,
1988[Medline].
26.
Muurahainen, NE,
Kissileff HR,
Lachaussee J,
and
Pi-Sunyer FX.
Effect of a soup preload on reduction of food intake by cholecystokinin in humans.
Am J Physiol Regulatory Integrative Comp Physiol
260:
R672-R680,
1991
27.
Reidelberger, RD,
Kalogeris TJ,
and
Solomon TE.
Plasma CCK levels after food intake and infusion of CCK analogues that inhibit feeding in dogs.
Am J Physiol Regulatory Integrative Comp Physiol
256:
R1148-R1154,
1989
28.
Rossi, L,
Drewe J,
Hildebrand P,
and
Beglinger C.
Role of cholecystokinin (CCK) in the control of phenylalanine-induced inhibition of food intake in man (Abstract).
Digestion
54:
305,
1993.
29.
Sachs, L.
Angewandte Statistik. Berlin: Springer, 1984.
30.
SAS Institute.
SAS Release 6.03. Cary, NC: SAS Inst, 1984.
31.
Schick, RR,
Schusdziarra V,
Mossner J,
Neuberger J,
Schroder B,
Segmuller R,
Maier V,
and
Classen M.
Effect of CCK on food intake in man: physiological or pharmacological effect?
Z Gastroenterol
29:
53-58,
1991[ISI][Medline].
32.
Schmidt, WE,
Creutzfeldt W,
Hocker M,
Nustede R,
Choudhury AR,
Schleser A,
Rovati LC,
and
Folsch UR.
Cholecystokinin receptor antagonist loxiglumide modulates plasma levels of gastro-entero-pancreatic hormones in man. Feedback control of cholecystokinin and gastrin secretion.
Eur J Clin Invest
21:
501-511,
1991[ISI][Medline].
33.
Schmidt, WE,
Creutzfeldt W,
Schleser A,
Choudhury AR,
Nustede R,
Hocker M,
Nitsche R,
Sostmann H,
Rovati LC,
and
Folsch UR.
Role of CCK in regulation of pancreaticobiliary functions and GI motility in humans: effects of loxiglumide.
Am J Physiol Gastrointest Liver Physiol
260:
G197-G206,
1991
34.
Schmidt, WE,
Schenk S,
Nustede R,
Holst JJ,
Folsch UR,
and
Creutzfeldt W.
Cholecystokinin is a negative regulator of gastric acid secretion and postprandial release of gastrin in humans.
Gastroenterology
107:
1610-1620,
1994[ISI][Medline].
35.
Silver, AJ,
Flood JF,
Song AM,
and
Morley JE.
Evidence for a physiological role for CCK in the regulation of food intake in mice.
Am J Physiol Regulatory Integrative Comp Physiol
256:
R646-R652,
1989
36.
Stacher, G.
Satiety effects of cholecystokinin and ceruletide in lean and obese man.
Ann NY Acad Sci
448:
431-436,
1985[Abstract].
37.
Welch, I,
Saunders K,
and
Read NW.
Effect of ileal and intravenous infusions of fat emulsions on feeding and satiety in human volunteers.
Gastroenterology
89:
1293-1297,
1985[ISI][Medline].
38.
Welch, IM,
Sepple CP,
and
Read NW.
Comparisons of the effects on satiety and eating behaviour of infusion of lipid into the different regions of the small intestine.
Gut
29:
306-311,
1988
39.
Weller, A,
Smith GP,
and
Gibbs J.
Endogenous cholecystokinin reduces feeding in young rats.
Science
247:
1589-1591,
1990
40.
Wolkowitz, OM,
Gertz B,
Weingartner H,
Beccaria L,
Thompson K,
and
Liddle RA.
Hunger in humans induced by MK-329, a specific peripheral-type cholecystokinin receptor antagonist.
Biol Psychiatry
28:
169-173,
1990[ISI][Medline].
This article has been cited by other articles:
|
|
 |
|
  L. Degen, J. Drewe, F. Piccoli, K. Grani, S. Oesch, R. Bunea, M. D'Amato, and C. Beglinger Effect of CCK-1 receptor blockade on ghrelin and PYY secretion in men Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2007; 292(4): R1391 - R1399. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. A. Blom, A. Lluch, A. Stafleu, S. Vinoy, J. J Holst, G. Schaafsma, and H. F. Hendriks Effect of a high-protein breakfast on the postprandial ghrelin response Am. J. Clinical Nutrition, February 1, 2006; 83(2): 211 - 220. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Oesch, L. Degen, and C. Beglinger Effect of a protein preload on food intake and satiety feelings in response to duodenal fat perfusions in healthy male subjects Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2005; 289(4): R1042 - R1047. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. M. Brennan, K. L. Feltrin, M. Horowitz, A. J. P. M. Smout, J. H. Meyer, J. Wishart, and C. Feinle-Bisset Evaluation of interactions between CCK and GLP-1 in their effects on appetite, energy intake, and antropyloroduodenal motility in healthy men Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2005; 288(6): R1477 - R1485. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Zheng, M. W. Lewis, and R. A. Travagli In vitro analysis of the effects of cholecystokinin on rat brain stem motoneurons Am J Physiol Gastrointest Liver Physiol, May 1, 2005; 288(5): G1066 - G1073. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. L. Feltrin, T. J. Little, J. H. Meyer, M. Horowitz, A. J. P. M. Smout, J. Wishart, A. N. Pilichiewicz, T. Rades, I. M. Chapman, and C. Feinle-Bisset Effects of intraduodenal fatty acids on appetite, antropyloroduodenal motility, and plasma CCK and GLP-1 in humans vary with their chain length Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2004; 287(3): R524 - R533. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-P. Gutzwiller, L. Degen, D. Matzinger, S. Prestin, and C. Beglinger Interaction between GLP-1 and CCK-33 in inhibiting food intake and appetite in men Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2004; 287(3): R562 - R567. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. de Graaf, W. A. Blom, P. A. Smeets, A. Stafleu, and H. F. Hendriks Biomarkers of satiation and satiety Am. J. Clinical Nutrition, June 1, 2004; 79(6): 946 - 961. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. R. Kissileff, J. C. Carretta, A. Geliebter, and F. X. Pi-Sunyer Cholecystokinin and stomach distension combine to reduce food intake in humans Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2003; 285(5): R992 - R998. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. A. Cupples Regulation of body weight Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2002; 282(5): R1264 - R1266. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
